img

Global JE Inactivated Vaccine Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global JE Inactivated Vaccine Market Insights, Forecast to 2034

Inactivated vaccines are safer
Global JE Inactivated Vaccine market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, JE Inactivated Vaccine industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global JE Inactivated Vaccine market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global JE Inactivated Vaccine market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Bharat Biotech
Biological E. Limited
Biken
Seqirus
Liaoning Chengda
Valneva Austria GmbH
Segment by Type
Hamster Kidney Cells
Vero Cells

Segment by Application


Hospital
Clinic

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ JE Inactivated Vaccine plant distribution, commercial date of JE Inactivated Vaccine, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, JE Inactivated Vaccine introduction, etc. JE Inactivated Vaccine Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of JE Inactivated Vaccine
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 JE Inactivated Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global JE Inactivated Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Hamster Kidney Cells
1.2.3 Vero Cells
1.3 Market by Application
1.3.1 Global JE Inactivated Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global JE Inactivated Vaccine Sales Estimates and Forecasts 2018-2029
2.2 Global JE Inactivated Vaccine Revenue by Region
2.2.1 Global JE Inactivated Vaccine Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global JE Inactivated Vaccine Revenue by Region (2018-2024)
2.2.3 Global JE Inactivated Vaccine Revenue by Region (2024-2029)
2.2.4 Global JE Inactivated Vaccine Revenue Market Share by Region (2018-2029)
2.3 Global JE Inactivated Vaccine Sales Estimates and Forecasts 2018-2029
2.4 Global JE Inactivated Vaccine Sales by Region
2.4.1 Global JE Inactivated Vaccine Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global JE Inactivated Vaccine Sales by Region (2018-2024)
2.4.3 Global JE Inactivated Vaccine Sales by Region (2024-2029)
2.4.4 Global JE Inactivated Vaccine Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global JE Inactivated Vaccine Sales by Manufacturers
3.1.1 Global JE Inactivated Vaccine Sales by Manufacturers (2018-2024)
3.1.2 Global JE Inactivated Vaccine Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of JE Inactivated Vaccine in 2022
3.2 Global JE Inactivated Vaccine Revenue by Manufacturers
3.2.1 Global JE Inactivated Vaccine Revenue by Manufacturers (2018-2024)
3.2.2 Global JE Inactivated Vaccine Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by JE Inactivated Vaccine Revenue in 2022
3.3 Global Key Players of JE Inactivated Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global JE Inactivated Vaccine Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global JE Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of JE Inactivated Vaccine, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of JE Inactivated Vaccine, Product Offered and Application
3.8 Global Key Manufacturers of JE Inactivated Vaccine, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global JE Inactivated Vaccine Sales by Type
4.1.1 Global JE Inactivated Vaccine Historical Sales by Type (2018-2024)
4.1.2 Global JE Inactivated Vaccine Forecasted Sales by Type (2024-2029)
4.1.3 Global JE Inactivated Vaccine Sales Market Share by Type (2018-2029)
4.2 Global JE Inactivated Vaccine Revenue by Type
4.2.1 Global JE Inactivated Vaccine Historical Revenue by Type (2018-2024)
4.2.2 Global JE Inactivated Vaccine Forecasted Revenue by Type (2024-2029)
4.2.3 Global JE Inactivated Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global JE Inactivated Vaccine Price by Type
4.3.1 Global JE Inactivated Vaccine Price by Type (2018-2024)
4.3.2 Global JE Inactivated Vaccine Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global JE Inactivated Vaccine Sales by Application
5.1.1 Global JE Inactivated Vaccine Historical Sales by Application (2018-2024)
5.1.2 Global JE Inactivated Vaccine Forecasted Sales by Application (2024-2029)
5.1.3 Global JE Inactivated Vaccine Sales Market Share by Application (2018-2029)
5.2 Global JE Inactivated Vaccine Revenue by Application
5.2.1 Global JE Inactivated Vaccine Historical Revenue by Application (2018-2024)
5.2.2 Global JE Inactivated Vaccine Forecasted Revenue by Application (2024-2029)
5.2.3 Global JE Inactivated Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global JE Inactivated Vaccine Price by Application
5.3.1 Global JE Inactivated Vaccine Price by Application (2018-2024)
5.3.2 Global JE Inactivated Vaccine Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada JE Inactivated Vaccine Market Size by Type
6.1.1 US & Canada JE Inactivated Vaccine Sales by Type (2018-2029)
6.1.2 US & Canada JE Inactivated Vaccine Revenue by Type (2018-2029)
6.2 US & Canada JE Inactivated Vaccine Market Size by Application
6.2.1 US & Canada JE Inactivated Vaccine Sales by Application (2018-2029)
6.2.2 US & Canada JE Inactivated Vaccine Revenue by Application (2018-2029)
6.3 US & Canada JE Inactivated Vaccine Market Size by Country
6.3.1 US & Canada JE Inactivated Vaccine Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada JE Inactivated Vaccine Sales by Country (2018-2029)
6.3.3 US & Canada JE Inactivated Vaccine Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe JE Inactivated Vaccine Market Size by Type
7.1.1 Europe JE Inactivated Vaccine Sales by Type (2018-2029)
7.1.2 Europe JE Inactivated Vaccine Revenue by Type (2018-2029)
7.2 Europe JE Inactivated Vaccine Market Size by Application
7.2.1 Europe JE Inactivated Vaccine Sales by Application (2018-2029)
7.2.2 Europe JE Inactivated Vaccine Revenue by Application (2018-2029)
7.3 Europe JE Inactivated Vaccine Market Size by Country
7.3.1 Europe JE Inactivated Vaccine Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe JE Inactivated Vaccine Sales by Country (2018-2029)
7.3.3 Europe JE Inactivated Vaccine Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China JE Inactivated Vaccine Market Size
8.1.1 China JE Inactivated Vaccine Sales (2018-2029)
8.1.2 China JE Inactivated Vaccine Revenue (2018-2029)
8.2 China JE Inactivated Vaccine Market Size by Application
8.2.1 China JE Inactivated Vaccine Sales by Application (2018-2029)
8.2.2 China JE Inactivated Vaccine Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia JE Inactivated Vaccine Market Size by Type
9.1.1 Asia JE Inactivated Vaccine Sales by Type (2018-2029)
9.1.2 Asia JE Inactivated Vaccine Revenue by Type (2018-2029)
9.2 Asia JE Inactivated Vaccine Market Size by Application
9.2.1 Asia JE Inactivated Vaccine Sales by Application (2018-2029)
9.2.2 Asia JE Inactivated Vaccine Revenue by Application (2018-2029)
9.3 Asia JE Inactivated Vaccine Sales by Region
9.3.1 Asia JE Inactivated Vaccine Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia JE Inactivated Vaccine Revenue by Region (2018-2029)
9.3.3 Asia JE Inactivated Vaccine Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America JE Inactivated Vaccine Market Size by Type
10.1.1 Middle East, Africa and Latin America JE Inactivated Vaccine Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America JE Inactivated Vaccine Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America JE Inactivated Vaccine Market Size by Application
10.2.1 Middle East, Africa and Latin America JE Inactivated Vaccine Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America JE Inactivated Vaccine Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America JE Inactivated Vaccine Sales by Country
10.3.1 Middle East, Africa and Latin America JE Inactivated Vaccine Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America JE Inactivated Vaccine Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America JE Inactivated Vaccine Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Bharat Biotech
11.1.1 Bharat Biotech Company Information
11.1.2 Bharat Biotech Overview
11.1.3 Bharat Biotech JE Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Bharat Biotech JE Inactivated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Bharat Biotech Recent Developments
11.2 Biological E. Limited
11.2.1 Biological E. Limited Company Information
11.2.2 Biological E. Limited Overview
11.2.3 Biological E. Limited JE Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Biological E. Limited JE Inactivated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Biological E. Limited Recent Developments
11.3 Biken
11.3.1 Biken Company Information
11.3.2 Biken Overview
11.3.3 Biken JE Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Biken JE Inactivated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Biken Recent Developments
11.4 Seqirus
11.4.1 Seqirus Company Information
11.4.2 Seqirus Overview
11.4.3 Seqirus JE Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Seqirus JE Inactivated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Seqirus Recent Developments
11.5 Liaoning Chengda
11.5.1 Liaoning Chengda Company Information
11.5.2 Liaoning Chengda Overview
11.5.3 Liaoning Chengda JE Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Liaoning Chengda JE Inactivated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Liaoning Chengda Recent Developments
11.6 Valneva Austria GmbH
11.6.1 Valneva Austria GmbH Company Information
11.6.2 Valneva Austria GmbH Overview
11.6.3 Valneva Austria GmbH JE Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Valneva Austria GmbH JE Inactivated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Valneva Austria GmbH Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 JE Inactivated Vaccine Industry Chain Analysis
12.2 JE Inactivated Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 JE Inactivated Vaccine Production Mode & Process
12.4 JE Inactivated Vaccine Sales and Marketing
12.4.1 JE Inactivated Vaccine Sales Channels
12.4.2 JE Inactivated Vaccine Distributors
12.5 JE Inactivated Vaccine Customers
13 Market Dynamics
13.1 JE Inactivated Vaccine Industry Trends
13.2 JE Inactivated Vaccine Market Drivers
13.3 JE Inactivated Vaccine Market Challenges
13.4 JE Inactivated Vaccine Market Restraints
14 Key Findings in The Global JE Inactivated Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global JE Inactivated Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Hamster Kidney Cells
Table 3. Major Manufacturers of Vero Cells
Table 4. Global JE Inactivated Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 5. Global JE Inactivated Vaccine Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global JE Inactivated Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global JE Inactivated Vaccine Revenue by Region (2024-2029) & (US$ Million)
Table 8. Global JE Inactivated Vaccine Revenue Market Share by Region (2018-2024)
Table 9. Global JE Inactivated Vaccine Revenue Market Share by Region (2024-2029)
Table 10. Global JE Inactivated Vaccine Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 11. Global JE Inactivated Vaccine Sales by Region (2018-2024) & (K Units)
Table 12. Global JE Inactivated Vaccine Sales by Region (2024-2029) & (K Units)
Table 13. Global JE Inactivated Vaccine Sales Market Share by Region (2018-2024)
Table 14. Global JE Inactivated Vaccine Sales Market Share by Region (2024-2029)
Table 15. Global JE Inactivated Vaccine Sales by Manufacturers (2018-2024) & (K Units)
Table 16. Global JE Inactivated Vaccine Sales Share by Manufacturers (2018-2024)
Table 17. Global JE Inactivated Vaccine Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global JE Inactivated Vaccine Revenue Share by Manufacturers (2018-2024)
Table 19. Global Key Players of JE Inactivated Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
Table 20. JE Inactivated Vaccine Price by Manufacturers 2018-2024 (US$/Unit)
Table 21. Global JE Inactivated Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global JE Inactivated Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in JE Inactivated Vaccine as of 2022)
Table 23. Global Key Manufacturers of JE Inactivated Vaccine, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of JE Inactivated Vaccine, Product Offered and Application
Table 25. Global Key Manufacturers of JE Inactivated Vaccine, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global JE Inactivated Vaccine Sales by Type (2018-2024) & (K Units)
Table 28. Global JE Inactivated Vaccine Sales by Type (2024-2029) & (K Units)
Table 29. Global JE Inactivated Vaccine Sales Share by Type (2018-2024)
Table 30. Global JE Inactivated Vaccine Sales Share by Type (2024-2029)
Table 31. Global JE Inactivated Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global JE Inactivated Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 33. Global JE Inactivated Vaccine Revenue Share by Type (2018-2024)
Table 34. Global JE Inactivated Vaccine Revenue Share by Type (2024-2029)
Table 35. JE Inactivated Vaccine Price by Type (2018-2024) & (US$/Unit)
Table 36. Global JE Inactivated Vaccine Price Forecast by Type (2024-2029) & (US$/Unit)
Table 37. Global JE Inactivated Vaccine Sales by Application (2018-2024) & (K Units)
Table 38. Global JE Inactivated Vaccine Sales by Application (2024-2029) & (K Units)
Table 39. Global JE Inactivated Vaccine Sales Share by Application (2018-2024)
Table 40. Global JE Inactivated Vaccine Sales Share by Application (2024-2029)
Table 41. Global JE Inactivated Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global JE Inactivated Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 43. Global JE Inactivated Vaccine Revenue Share by Application (2018-2024)
Table 44. Global JE Inactivated Vaccine Revenue Share by Application (2024-2029)
Table 45. JE Inactivated Vaccine Price by Application (2018-2024) & (US$/Unit)
Table 46. Global JE Inactivated Vaccine Price Forecast by Application (2024-2029) & (US$/Unit)
Table 47. US & Canada JE Inactivated Vaccine Sales by Type (2018-2024) & (K Units)
Table 48. US & Canada JE Inactivated Vaccine Sales by Type (2024-2029) & (K Units)
Table 49. US & Canada JE Inactivated Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 50. US & Canada JE Inactivated Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 51. US & Canada JE Inactivated Vaccine Sales by Application (2018-2024) & (K Units)
Table 52. US & Canada JE Inactivated Vaccine Sales by Application (2024-2029) & (K Units)
Table 53. US & Canada JE Inactivated Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 54. US & Canada JE Inactivated Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 55. US & Canada JE Inactivated Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 56. US & Canada JE Inactivated Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 57. US & Canada JE Inactivated Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 58. US & Canada JE Inactivated Vaccine Sales by Country (2018-2024) & (K Units)
Table 59. US & Canada JE Inactivated Vaccine Sales by Country (2024-2029) & (K Units)
Table 60. Europe JE Inactivated Vaccine Sales by Type (2018-2024) & (K Units)
Table 61. Europe JE Inactivated Vaccine Sales by Type (2024-2029) & (K Units)
Table 62. Europe JE Inactivated Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 63. Europe JE Inactivated Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 64. Europe JE Inactivated Vaccine Sales by Application (2018-2024) & (K Units)
Table 65. Europe JE Inactivated Vaccine Sales by Application (2024-2029) & (K Units)
Table 66. Europe JE Inactivated Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 67. Europe JE Inactivated Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 68. Europe JE Inactivated Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 69. Europe JE Inactivated Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 70. Europe JE Inactivated Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 71. Europe JE Inactivated Vaccine Sales by Country (2018-2024) & (K Units)
Table 72. Europe JE Inactivated Vaccine Sales by Country (2024-2029) & (K Units)
Table 73. China JE Inactivated Vaccine Sales by Type (2018-2024) & (K Units)
Table 74. China JE Inactivated Vaccine Sales by Type (2024-2029) & (K Units)
Table 75. China JE Inactivated Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 76. China JE Inactivated Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 77. China JE Inactivated Vaccine Sales by Application (2018-2024) & (K Units)
Table 78. China JE Inactivated Vaccine Sales by Application (2024-2029) & (K Units)
Table 79. China JE Inactivated Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 80. China JE Inactivated Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 81. Asia JE Inactivated Vaccine Sales by Type (2018-2024) & (K Units)
Table 82. Asia JE Inactivated Vaccine Sales by Type (2024-2029) & (K Units)
Table 83. Asia JE Inactivated Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 84. Asia JE Inactivated Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 85. Asia JE Inactivated Vaccine Sales by Application (2018-2024) & (K Units)
Table 86. Asia JE Inactivated Vaccine Sales by Application (2024-2029) & (K Units)
Table 87. Asia JE Inactivated Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 88. Asia JE Inactivated Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 89. Asia JE Inactivated Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 90. Asia JE Inactivated Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 91. Asia JE Inactivated Vaccine Revenue by Region (2024-2029) & (US$ Million)
Table 92. Asia JE Inactivated Vaccine Sales by Region (2018-2024) & (K Units)
Table 93. Asia JE Inactivated Vaccine Sales by Region (2024-2029) & (K Units)
Table 94. Middle East, Africa and Latin America JE Inactivated Vaccine Sales by Type (2018-2024) & (K Units)
Table 95. Middle East, Africa and Latin America JE Inactivated Vaccine Sales by Type (2024-2029) & (K Units)
Table 96. Middle East, Africa and Latin America JE Inactivated Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 97. Middle East, Africa and Latin America JE Inactivated Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 98. Middle East, Africa and Latin America JE Inactivated Vaccine Sales by Application (2018-2024) & (K Units)
Table 99. Middle East, Africa and Latin America JE Inactivated Vaccine Sales by Application (2024-2029) & (K Units)
Table 100. Middle East, Africa and Latin America JE Inactivated Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 101. Middle East, Africa and Latin America JE Inactivated Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 102. Middle East, Africa and Latin America JE Inactivated Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 103. Middle East, Africa and Latin America JE Inactivated Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America JE Inactivated Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 105. Middle East, Africa and Latin America JE Inactivated Vaccine Sales by Country (2018-2024) & (K Units)
Table 106. Middle East, Africa and Latin America JE Inactivated Vaccine Sales by Country (2024-2029) & (K Units)
Table 107. Bharat Biotech Company Information
Table 108. Bharat Biotech Description and Major Businesses
Table 109. Bharat Biotech JE Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 110. Bharat Biotech JE Inactivated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Bharat Biotech Recent Developments
Table 112. Biological E. Limited Company Information
Table 113. Biological E. Limited Description and Major Businesses
Table 114. Biological E. Limited JE Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 115. Biological E. Limited JE Inactivated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Biological E. Limited Recent Developments
Table 117. Biken Company Information
Table 118. Biken Description and Major Businesses
Table 119. Biken JE Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 120. Biken JE Inactivated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Biken Recent Developments
Table 122. Seqirus Company Information
Table 123. Seqirus Description and Major Businesses
Table 124. Seqirus JE Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 125. Seqirus JE Inactivated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Seqirus Recent Developments
Table 127. Liaoning Chengda Company Information
Table 128. Liaoning Chengda Description and Major Businesses
Table 129. Liaoning Chengda JE Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 130. Liaoning Chengda JE Inactivated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Liaoning Chengda Recent Developments
Table 132. Valneva Austria GmbH Company Information
Table 133. Valneva Austria GmbH Description and Major Businesses
Table 134. Valneva Austria GmbH JE Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 135. Valneva Austria GmbH JE Inactivated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Valneva Austria GmbH Recent Developments
Table 137. Key Raw Materials Lists
Table 138. Raw Materials Key Suppliers Lists
Table 139. JE Inactivated Vaccine Distributors List
Table 140. JE Inactivated Vaccine Customers List
Table 141. JE Inactivated Vaccine Market Trends
Table 142. JE Inactivated Vaccine Market Drivers
Table 143. JE Inactivated Vaccine Market Challenges
Table 144. JE Inactivated Vaccine Market Restraints
Table 145. Research Programs/Design for This Report
Table 146. Key Data Information from Secondary Sources
Table 147. Key Data Information from Primary Sources
List of Figures
Figure 1. JE Inactivated Vaccine Product Picture
Figure 2. Global JE Inactivated Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global JE Inactivated Vaccine Market Share by Type in 2022 & 2029
Figure 4. Hamster Kidney Cells Product Picture
Figure 5. Vero Cells Product Picture
Figure 6. Global JE Inactivated Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global JE Inactivated Vaccine Market Share by Application in 2022 & 2029
Figure 8. Hospital
Figure 9. Clinic
Figure 10. JE Inactivated Vaccine Report Years Considered
Figure 11. Global JE Inactivated Vaccine Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 12. Global JE Inactivated Vaccine Revenue 2018-2029 (US$ Million)
Figure 13. Global JE Inactivated Vaccine Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 14. Global JE Inactivated Vaccine Revenue Market Share by Region (2018-2029)
Figure 15. Global JE Inactivated Vaccine Sales 2018-2029 ((K Units)
Figure 16. Global JE Inactivated Vaccine Sales Market Share by Region (2018-2029)
Figure 17. US & Canada JE Inactivated Vaccine Sales YoY (2018-2029) & (K Units)
Figure 18. US & Canada JE Inactivated Vaccine Revenue YoY (2018-2029) & (US$ Million)
Figure 19. Europe JE Inactivated Vaccine Sales YoY (2018-2029) & (K Units)
Figure 20. Europe JE Inactivated Vaccine Revenue YoY (2018-2029) & (US$ Million)
Figure 21. China JE Inactivated Vaccine Sales YoY (2018-2029) & (K Units)
Figure 22. China JE Inactivated Vaccine Revenue YoY (2018-2029) & (US$ Million)
Figure 23. Asia (excluding China) JE Inactivated Vaccine Sales YoY (2018-2029) & (K Units)
Figure 24. Asia (excluding China) JE Inactivated Vaccine Revenue YoY (2018-2029) & (US$ Million)
Figure 25. Middle East, Africa and Latin America JE Inactivated Vaccine Sales YoY (2018-2029) & (K Units)
Figure 26. Middle East, Africa and Latin America JE Inactivated Vaccine Revenue YoY (2018-2029) & (US$ Million)
Figure 27. The JE Inactivated Vaccine Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 28. The Top 5 and 10 Largest Manufacturers of JE Inactivated Vaccine in the World: Market Share by JE Inactivated Vaccine Revenue in 2022
Figure 29. Global JE Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 30. Global JE Inactivated Vaccine Sales Market Share by Type (2018-2029)
Figure 31. Global JE Inactivated Vaccine Revenue Market Share by Type (2018-2029)
Figure 32. Global JE Inactivated Vaccine Sales Market Share by Application (2018-2029)
Figure 33. Global JE Inactivated Vaccine Revenue Market Share by Application (2018-2029)
Figure 34. US & Canada JE Inactivated Vaccine Sales Market Share by Type (2018-2029)
Figure 35. US & Canada JE Inactivated Vaccine Revenue Market Share by Type (2018-2029)
Figure 36. US & Canada JE Inactivated Vaccine Sales Market Share by Application (2018-2029)
Figure 37. US & Canada JE Inactivated Vaccine Revenue Market Share by Application (2018-2029)
Figure 38. US & Canada JE Inactivated Vaccine Revenue Share by Country (2018-2029)
Figure 39. US & Canada JE Inactivated Vaccine Sales Share by Country (2018-2029)
Figure 40. U.S. JE Inactivated Vaccine Revenue (2018-2029) & (US$ Million)
Figure 41. Canada JE Inactivated Vaccine Revenue (2018-2029) & (US$ Million)
Figure 42. Europe JE Inactivated Vaccine Sales Market Share by Type (2018-2029)
Figure 43. Europe JE Inactivated Vaccine Revenue Market Share by Type (2018-2029)
Figure 44. Europe JE Inactivated Vaccine Sales Market Share by Application (2018-2029)
Figure 45. Europe JE Inactivated Vaccine Revenue Market Share by Application (2018-2029)
Figure 46. Europe JE Inactivated Vaccine Revenue Share by Country (2018-2029)
Figure 47. Europe JE Inactivated Vaccine Sales Share by Country (2018-2029)
Figure 48. Germany JE Inactivated Vaccine Revenue (2018-2029) & (US$ Million)
Figure 49. France JE Inactivated Vaccine Revenue (2018-2029) & (US$ Million)
Figure 50. U.K. JE Inactivated Vaccine Revenue (2018-2029) & (US$ Million)
Figure 51. Italy JE Inactivated Vaccine Revenue (2018-2029) & (US$ Million)
Figure 52. Russia JE Inactivated Vaccine Revenue (2018-2029) & (US$ Million)
Figure 53. China JE Inactivated Vaccine Sales Market Share by Type (2018-2029)
Figure 54. China JE Inactivated Vaccine Revenue Market Share by Type (2018-2029)
Figure 55. China JE Inactivated Vaccine Sales Market Share by Application (2018-2029)
Figure 56. China JE Inactivated Vaccine Revenue Market Share by Application (2018-2029)
Figure 57. Asia JE Inactivated Vaccine Sales Market Share by Type (2018-2029)
Figure 58. Asia JE Inactivated Vaccine Revenue Market Share by Type (2018-2029)
Figure 59. Asia JE Inactivated Vaccine Sales Market Share by Application (2018-2029)
Figure 60. Asia JE Inactivated Vaccine Revenue Market Share by Application (2018-2029)
Figure 61. Asia JE Inactivated Vaccine Revenue Share by Region (2018-2029)
Figure 62. Asia JE Inactivated Vaccine Sales Share by Region (2018-2029)
Figure 63. Japan JE Inactivated Vaccine Revenue (2018-2029) & (US$ Million)
Figure 64. South Korea JE Inactivated Vaccine Revenue (2018-2029) & (US$ Million)
Figure 65. China Taiwan JE Inactivated Vaccine Revenue (2018-2029) & (US$ Million)
Figure 66. Southeast Asia JE Inactivated Vaccine Revenue (2018-2029) & (US$ Million)
Figure 67. India JE Inactivated Vaccine Revenue (2018-2029) & (US$ Million)
Figure 68. Middle East, Africa and Latin America JE Inactivated Vaccine Sales Market Share by Type (2018-2029)
Figure 69. Middle East, Africa and Latin America JE Inactivated Vaccine Revenue Market Share by Type (2018-2029)
Figure 70. Middle East, Africa and Latin America JE Inactivated Vaccine Sales Market Share by Application (2018-2029)
Figure 71. Middle East, Africa and Latin America JE Inactivated Vaccine Revenue Market Share by Application (2018-2029)
Figure 72. Middle East, Africa and Latin America JE Inactivated Vaccine Revenue Share by Country (2018-2029)
Figure 73. Middle East, Africa and Latin America JE Inactivated Vaccine Sales Share by Country (2018-2029)
Figure 74. Brazil JE Inactivated Vaccine Revenue (2018-2029) & (US$ Million)
Figure 75. Mexico JE Inactivated Vaccine Revenue (2018-2029) & (US$ Million)
Figure 76. Turkey JE Inactivated Vaccine Revenue (2018-2029) & (US$ Million)
Figure 77. Israel JE Inactivated Vaccine Revenue (2018-2029) & (US$ Million)
Figure 78. GCC Countries JE Inactivated Vaccine Revenue (2018-2029) & (US$ Million)
Figure 79. JE Inactivated Vaccine Value Chain
Figure 80. JE Inactivated Vaccine Production Process
Figure 81. Channels of Distribution
Figure 82. Distributors Profiles
Figure 83. Bottom-up and Top-down Approaches for This Report
Figure 84. Data Triangulation
Figure 85. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries